Qui ignore encore les liens entre les voies aériennes supérieures et les voies aériennes inférieures ?

1. Arif AA, Delclos GL, Lee ES, Tortolero SR, Whitehead LW. Prevalence and risk factors of asthma and wheezing among US adults: an analysis of the NHANES III data. Eur Respir J. 2003 May;21(5):827-33
2. Blaiss MS. Rhinitis-asthma connection: epidemiologic and pathophysiologic basis. Allergy Asthma Proc 2005; 26: 35–40
3. F. Thien, P.J Beggs, D. Csutoros. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planet Health 2018;2: e255–63

Innovations thérapeutiques dans l'asthme sévère 

1. hung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-73.
2. Global Strategy for Asthma Management and Prevention, (2022 updated). http://www.ginasthma.org
3. Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, et al. Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version. Revue des Maladies Respiratoires 38 (2022) 1048-1083.
4. GINA POCKET GUIDE : Difficult-to-treat & severe asthma adolescent and adult patients diagnosis and Management. April 2021. https://ginasthma.org/wp-content/uploads/2021/08/SA-Pocket-guide-v3.0
5. Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ open research. 2018;4:00125-2017.
6. Menzella F, Ballarin A, Sartor M, Floriani AF et al. Comparison between clinical trials and real-world evidence studies on biologics for severe asthma. Int Med Res. 2022 Nov;50(11):3000605221133689.
7. Xolair + Ridolo E et al. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Human Vaccines & immunotherapeutics. 2020;16(10)2349-2356

La classification des rhinites chroniques 

1. Park DY, Lee YJ, Kim DK, Kim SW, Yang HJ, Kim DH, et al. KAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management. Allergy Asthma Immunol Res. 2023;15(2):145-59.
2. Papadopoulou A, Lambidi S, Lagousi T, Syrrou M, Giannoula F, Staikou E, et al. Nasal eosinophilia as a preliminary discriminative biomarker of non-allergic rhinitis in every day clinical pediatric practice. Eur Arch Otorhinolaryngol. 2023;280(4):1775-84.
3. Eckrich J, Hinkel J, Fischl A, Herrmann E, Holtappels G, Bachert C, et al. Nasal IgE in subjects with allergic and non-allergic rhinitis. World Allergy Organ J. 2020;13(6):100129.
4. Fu X, Du B, Meng Y, Li Y, Zhu X, Ou Z, et al. Associations between environmental characteristics, high-resolution indoor microbiome, metabolome and allergic and non-allergic rhinitis symptoms for junior high school students. Environ Sci Process Impacts.

Biologie de l'allergie 

1. Chabane H, et al. Nouvelles recommandations franc ̧ aises en biologie de l’allergie, synthèse. Rev Fr Allergol (2020),https://doi.org/10.1016/j.reval.2020.02.003
2. PUBLICATION du GUS de la SFD: Urticaire chronique: Actualités physiopathologiques et retentissement sur la prise en charge. Décembre 2014.
3. HAS. Prise en charge de l’urticaire chronique. Conférence de consensus RECOMMANDATION DE BONNE PRATIQUE - Mis en ligne le 01 janv. 2003
4. SFORL. RECOMMANDATION POUR LA PRATIQUE CLINIQUE Prise en charge diagnostique et thérapeutique des Rhinites Allergiques par l’ORL (hors rhinites professionnelles)
5. Recommandations pour la prescription de l’immunothérapie allergenique et le suivi du patient – méthodologie et liste des recommandations D. Caimmi, P. Demoly, groupe APSI 1, comité de rédacteurs et de relecteurs des recommandations françaises pour
   l’ITA respiratoire https://doi.org/10.1016/j.reval.2020.09.019
6. Wollenberg A et al; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020.

Intolérances alimentaires : gare à la biologie 

1. Les dosages d’IgG anti-aliments : méthodes et pertinence clinique des résultats. Position du groupe de travail de biologie de la Société française d’allergologie - 04/06/18. Anti-food IgG assays: Methods and clinical relevance of results. Position of the biology task
   force of the French society of allergy Doi : 10.1016/j.reval.2018.01.007. Chabane , V. Doyen , F. Bienvenu , K. Adel-Patient , J. Vitte , D. Mariotte , J. Bienvenu. Groupe de travail de biologie de la SFA

Prévention des infections respiratoires par la désensibilisation chez les asthmatiques allergiques : la preuve par l’épithélium !

1. Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, et al. Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version. Revue des Maladies Respiratoires 38 (2022) 1048-1083.
2. Global Strategy for Asthma Management and Prevention, (2022 updated). http://www.ginasthma.org
3. Woehlk C, Von Bülow A, Ghanizada M, Søndergaard MB, Hansen S, Porsbjerg C. Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological
   study. Eur Respir J. 2022 Nov 17;60(5):2200446.
4. Woehlk C, Ramu S, Sverrild A, Nieto-Fontarigo JJ, Vázquez-Mera S, Cerps S, et al. Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double Blind Randomized Controlled Trial. Am J Respir Crit Care
   Med. 2023 Jan 26. doi: 10.1164/rccm.202209-1708OC

Polypose naso-sinusienne de quoi s'agit-il ? 

1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
2. Han DH, Kim SW, Cho SH, Kim DY, Lee CH, Kim SS, et al. Predictors of bronchial hyperresponsiveness in chronic rhinosinusitis with nasal polyp. Allergy. 2009;64(1):118-22.
3. Lund VJ. Diagnosis and treatment of nasal polyps. BMJ. 1995;311(7017):1411-4
4. Alobid I, Benitez P, Valero A, Berenguer J, Bernal-Sprekelsen M, Picado C, et al. The impact of atopy, sinus opacification, and nasal patency on quality of life in patients with severe nasal polyposis. Otolaryngol Head Neck Surg. 2006;134(4):609-12.